Mounjaro®
Starting from £179.99/mo
Start journey Learn moreFeeling unusually tired on Mounjaro is one of the more common things people notice in the early weeks of treatment. Fatigue or lethargy affects a meaningful proportion of users, particularly after starting or moving up a dose. It is listed among the known side effects of tirzepatide, and for most people it settles as the body adjusts. That said, persistent or severe tiredness is worth discussing with your prescriber, because it can have more than one cause. Mounjaro is a prescription-only medicine; any decision about continuing, adjusting or pausing treatment should be made with a qualified clinician who knows your full picture.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
This is the decision that shapes everything else. Fatigue during Mounjaro treatment almost always has a root cause, and pinning it down helps you respond appropriately rather than simply waiting it out.
Tirzepatide slows the rate at which the stomach empties. That effect is intentional (it extends the feeling of fullness) but it also means your body is absorbing food energy more gradually than it was before. In the first weeks, especially if appetite has fallen sharply, overall calorie intake often drops faster than the body expects. The result can feel like running on less fuel than usual: a dull, persistent tiredness rather than the sharp exhaustion of poor sleep. The NHS medicines page for tirzepatide lists fatigue and dizziness among the side effects that can occur, particularly early in treatment.
There is a second possibility worth considering. Nausea and vomiting, which are more common early on or after a dose step-up, reduce fluid intake without people always realising it. Mild dehydration on its own is enough to produce significant lethargy. Keeping a bottle of water somewhere visible (next to the kettle, or wherever you start your morning) is a small habit that genuinely helps.
A third thread is less obvious but important: Mounjaro affects GIP receptors as well as GLP-1 receptors. Some researchers believe this dual action influences energy metabolism in ways that single-pathway medicines do not, though the clinical picture here is still developing. What that means practically is that the fatigue pattern on tirzepatide can feel slightly different from what people report on semaglutide, and that is not a reason for alarm. You can read more about how tirzepatide works on the tirzepatide overview page.
Once you have established that the tiredness is real and not explained by an unrelated illness, it is worth thinking through the variables that are within your control.
Protein intake is the one most people underestimate. When appetite falls on Mounjaro, it tends to fall across the board, and protein-rich foods (which take more effort to prepare and eat) often get skipped first. Low protein accelerates the loss of lean muscle tissue during weight loss, and muscle loss is a direct contributor to fatigue. Aiming to keep protein central to each meal, even when portions are small, is consistently what clinicians advise during treatment. Our page on building energy back up on Mounjaro covers practical strategies in more detail.
Sleep quality matters too. Significant changes in body weight and composition (including the early weeks of treatment) can affect sleep architecture in ways that are not always obvious. If you are waking earlier or sleeping less deeply than usual, the daytime tiredness may be compounding what the medicine itself is causing.
Dose timing is occasionally a factor. Some people find that injecting on a day when they have fewer demands the next morning (rather than, say, a Monday) reduces the impact of any post-injection fatigue on their working week. This is a personal logistics point, not a clinical instruction; timing questions belong in a conversation with your prescriber. The energy levels and Mounjaro page explores the interaction between dose schedule and daily fatigue in more depth.
Finally, context matters. If lethargy has arrived suddenly, feels different in character from the tiredness you have had before, or is accompanied by symptoms such as rapid heartbeat, breathlessness or confusion, it needs medical attention on its own terms, not reassurance that it is a known side effect.
For most people, the tiredness associated with starting Mounjaro or increasing a dose eases within one to three weeks, as the gastrointestinal adaptation settles and calorie intake stabilises at a new, lower level. That is the usual trajectory, and it is worth holding in mind when the first fortnight feels discouraging.
The decision to seek help sooner should be driven by severity and character rather than timing alone. If tiredness is stopping you from managing daily tasks, or if it is paired with persistent nausea severe enough to prevent adequate fluid intake, that combination warrants a call to your prescriber or pharmacy team rather than waiting. Dehydration from ongoing vomiting can, in turn, place strain on the kidneys — another reason the NHS guidance on tirzepatide emphasises contacting a doctor if GI symptoms are severe and prolonged.
People sometimes ask whether the fatigue means the medicine is not right for them. That is rarely the conclusion a prescriber would jump to early in treatment, but it is a legitimate question to raise at your next review. Dose progression can be slowed, or a step held longer, to give the body more time to adjust. At nume, every repeat order goes through a clinical review before dispatch, there is a real prescriber reading your update, and that is the right place to raise concerns about how you are feeling. If you are still working out whether Mounjaro is the right route, the consultation page sets out how that assessment works from the start.
There is also a broader Mounjaro overview (covering eligibility, results evidence and the full side-effect picture) on the Mounjaro treatment page, which is a useful reference alongside this one. For a closer look at the low-energy experience specifically, the low energy on Mounjaro page and the no energy on Mounjaro page address the more pronounced end of the fatigue spectrum. If you have questions about pricing and what is included in a private prescription, the cost context page covers that honestly.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.